NewsRoom Articles - Page 95 of 154 - PsychedelicNewsWire (PNW)

WednesdayJun 09, 2021 9:15 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files International Patent to Protect Potential Patient Coverage in 153 Countries

Cybin submits first-ever Patent Cooperation Treaty (“PCT”) filing By filing a single PCT application, the company simultaneously seeks protection for its proprietary drug treatments in a large number of countries Cybin filed the PCT application to provide broad international patent protection of key intellectual property Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to focus on its goal to improve the lives of those suffering from mental illness by changing the expectation of treatment. As part of that mission, the company has filed an international patent application that would provide the potential to obtain patent…

WednesdayJun 09, 2021 9:00 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Inks White Label Agreement as Strategic Planning Pays Off

White label agreement with FLO Brands outlines launch of cannabis vape product line PULL beginning to execute strategy to get white label products into provincial dispensaries, drive up to $3 million of annual revenue Nikolaevsky reports that “white labeling has also begun to build momentum and gain sales traction for us” Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic industry, announced that it has finalized a white label agreement to launch a line of cannabis vape products (https://ibn.fm/MfSkc). The agreement was made between Pure…

TuesdayJun 08, 2021 3:18 pm

Inaugural World Psychedelics Day – June 20th (6·20)

World Psychedelics Day (WPD), launches Sunday, June 20th, 2021, celebrating a new era of rational and informed perspectives on modern day psychedelics and traditional psychoactive plant medicines. This annual event honours the breakthroughs in scientific and therapeutic psychedelic research and traditional Indigenous practices that have culminated in the current “Psychedelic Renaissance”. Despite wide-reaching clinical applications, stigma and legal barriers still surround the use of psychedelics and psychoactive plant medicines. This year’s virtual event, produced by the Psychedelics Awareness Foundation*, a Canadian non-profit organization of artists, journalists, university students, parents and business people, seeks to redress this by teaming up with…

TuesdayJun 08, 2021 1:30 pm

Study Links Hallucinogen Use to Emotional Dysregulation, Risk Taking Among Youth

Unlike other hard drugs, hallucinogens such as LSD are seen as less likely to give rise to physical dependence and as less harmful. However, they are hardly safe, and sometimes their use is followed by unpredictable and intense psychological dependency, flashbacks and cognitive impairment. A lot of research has been done to investigate the relationship between the use of hallucinogens and personality. However, few studies have examined traits such as emotion dysregulation, sensation and risk seeking and impulsivity, which are all taken into account when studying other hard drugs. In an attempt to fill this research gap, a group of…

MondayJun 07, 2021 2:30 pm

Report Suggests That Use of Psychedelics May Improve Color Blindness

A recent study conducted proposes that psychedelic substances may reduce color blindness symptoms. The findings, which were reported in “Drug Sciences, Policy and Law,” discuss more than 20 anecdotal reports that describe how color blindness was improved after participants ingested drugs such as psilocybin and LSD. Historical and anecdotal reports have maintained for a while that psychedelic substances could adjust color vision. The researchers who conducted the study note that hurdles to carrying out more research on psychedelics have impeded further research on this. In prior studies, JEC Anthony and his colleagues accepted submissions from individuals who recorded changes in…

FridayJun 04, 2021 1:00 pm

Study Discovers Psilocybin May Have Lasting Benefits for Migraines

Researchers have been studying psilocybin in an attempt to discover any benefits the substance holds that may be useful to migraine sufferers. Psilocybin is found in magic mushrooms and is the main active ingredient responsible for the psychedelic effects mushrooms produce. The findings, which were reported in “Neurotherapeutics,” offer evidence that psilocybin may provide long-lasting therapeutic benefits to individuals who suffer from migraines. Over the years, anecdotal reports have claimed that psilocybin may lessen the symptoms of migraines. However, there hasn’t been enough scientific evidence to support these reports. This recently published study is the first placebo-controlled, double-blind study that…

FridayJun 04, 2021 9:30 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Opens Direct-To-Consumer Amazon Store under Pure Mushrooms Brand

PULL subsidiary Pure Mushrooms Corp. opens direct-to-consumer e-Commerce store on Amazon platform Store features Reishi, Maitake formulations with plans to add Lion’s Mane in summer 2021 Global functional mushroom market valued at $25.4 billion in 2020, expected CAGR of 8.44% from 2021-2026 Company expands psychedelic vertical through letter of intent with Psyence Group to co-produce psychedelic mushroom-based psilocybin formulations Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, recently announced that Pure Mushrooms Corp., its wholly owned subsidiary, has opened a direct-to-consumer, e-Commerce store…

ThursdayJun 03, 2021 3:00 pm

Deepak Chopra Plans to Raise Awareness About Healing Potential of Psychedelics

Last week, Deepak Chopra revealed that he’d entered into a new partnership with MindMed (NEO: MMED) (OTCQB: MMEDF), which aligned with his continued interest in mind-body healing. MindMed is a clinical-stage biotech company that is researching psychedelic medicine. In his statement, the self-care leader announced that the collaboration was for the public awareness of psychedelic research and public education, adding that while he didn’t believe psychedelics were a universal cure, they had a huge role to play in suicide prevention and the treatment of depression and post-traumatic stress disorder, among other conditions. A phase 3 clinical trial conducted by MindMed…

ThursdayJun 03, 2021 10:31 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Notes Impressive Advancement in Cannabis, Functional Mushrooms, Psilocybin Spaces

Pure Extracts’ BC facility is fully operational, ready to meet increasing demand for cannabis-based gummies, vapes, white label products Company’s involvement in functional, psychoactive mushrooms space is also gaining steam Pure Extracts’ current R&D focus is on psychoactive mushroom compounds Although the global pandemic extended its sales cycle, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is seeing interest from producers and brands looking for new opportunities and partnerships. Pure Extracts’ CEO Ben Nikolaevsky recently released a corporate update focused on three main points of interest — cannabis, functional mushrooms and psilocybin — in its growing business (https://ibn.fm/0v5sO). The update noted that…

ThursdayJun 03, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Targets Academic Collaborations to Advance Research on Largely Ignored Indications for Psilocybin

Psychedelics have been on the receiving end of groundbreaking research, which have greatly influenced the medical acceptance of the compounds Pharmaceutical developer Tryp Therapeutics is looking to use existing preclinical and clinical data to proceed directly to Phase 2a clinical trials The company intends to contribute to the growing body of research through academic collaborations with leading American institutions The research will focus on indications that other pharmaceutical companies have largely ignored Although we can accurately describe the psychedelics industry as nascent, psychedelics have been the subject of a flurry of groundbreaking research that have gradually lifted the stigma surrounding…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000